RxCelerate, the Cambridge-based out-sourced drug discovery and development leader, has unveiled a world-class Scientific Advisory Board (SAB) for its rapidly growing antibody discovery group, RxBiologics.
Data presented at AACR Annual Meeting in Chicago
Cambridge, UK – 29 April 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30. MB097 is an LBP in development as a co-therapy for immune checkpoint inhibitors (CPI) such as MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
One Nucleus is a dynamic not-for-profit Life Sciences and Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D has always been impactful in driving social and economic progress.
Pioneer Group, leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, and ZEISS, a global leader in optical and optoelectronic technology, have unveiled a strategic partnership.
The April edition of our People Pathways newsletter is available to read here!
Featuring:
✅ One Nucleus upcoming courses
✅ Blog including key takeaways from the 31 March skills roundtable
✅ Cyber awareness survey
✅ UCL Summer Courses
RESI Boston June 2025, will take place on June 16 at the Westin Copley Place during the Convention Week, followed by three (3) days of virtual partnering on June 17-18, 23. Virtual partnering on the June 23 gives you a chance to extend your Convention-week partnering! This hybrid format combines the benefits of in-person networking with the flexibility of online interactions.
Partnership to validate and promote the application of CN Bio’s PhysioMimix technology, with future opportunities for novel application and assay development
Amsbio has launched a new range of Deubiquitinating (DUB) enzyme assay kits supplied in a convenient and easy-to-use 96-well assay format. With minimal setup required and no need for substrate preparation, these ready-to-use kits accelerate routine DUB activity assays without compromising data quality.